| Literature DB >> 28538874 |
Catarina Tenório de Lima1, Paulo Sérgio Ramos de Araújo2,3, Heberton Medeiros de Teixeira4,5, Josemir Belo Dos Santos2,6, Vera Magalhães da Silveira2.
Abstract
BACKGROUND: : Kaposi's sarcoma continues to be the most common human immunodeficiency virus - associated neoplasm with considerable morbidity and mortality.Entities:
Mesh:
Year: 2017 PMID: 28538874 PMCID: PMC5429100 DOI: 10.1590/abd1806-4841.20175377
Source DB: PubMed Journal: An Bras Dermatol ISSN: 0365-0596 Impact factor: 1.896
Laboratory characteristics of patients with Kaposi's sarcoma living with HIV/AIDS, attended at an university hospital between 2004 and 2014
| Characteristics | Number | % |
|---|---|---|
| > 350 | 2 | 9.1 |
| 200 - 349 | 3 | 13.6 |
| < 200 | 17 | 77.3 |
| Undetectable | 1 | 4.5 |
| < 100,000 copies | 15 | 68.2 |
| > 100,000 copies | 3 | 13.6 |
| Unknown[ | 3 | 13.6 |
Note:
Information ignored - not on medical chart.
Main clinical manifestations of patients with Kaposi's sarcoma living with HIV/AIDS, attended at an university hospital between 2004 and 2014
| Characteristics | Number | % |
|---|---|---|
| Skin | 20 | 90.9 |
| Minimal oral lesion (hard palate) | 1 | 4.5 |
| Extensive oral lesion | 4 | 18.8 |
| Organs | 11 | 50.0 |
| Skin + Organs | 6 | 27.3 |
| Skin + Organs + Extensive oral lesion | 3 | 13.6 |
| Stomach | 8 | 53.3 |
| Colon | 3 | 20.0 |
| Lung | 2 | 13.3 |
| Spleen | 1 | 6.7 |
| Liver | 1 | 6.7 |
| No | 15 | 68.2 |
| Yes[ | 7 | 31.8 |
| Oroesophageal candidiasis | 4 | 57.1 |
| Herpes zoster | 2 | 28.6 |
| Neurotoxoplasmosis | 1 | 14.3 |
| Pulmonary tuberculosis | 1 | 14.3 |
| No | 6 | 27.3 |
| Yes[ | 16 | 72.7 |
| Oroesophageal candidiasis | 7 | 43.7 |
| Pulmonary and extrapulmonary tuberculosis | 4 | 25.0 |
| Neurotoxoplasmosis | 3 | 18.7 |
| Neurotoxoplasmosis | 2 | 12.5 |
| Pneumocystosis | 1 | 6.2 |
| Yes | 17 | 77.3 |
| No | 5 | 22.7 |
| No | 15 | 68.2 |
| Yes | 7 | 31.8 |
| Protease inhibitors | 2 | 28.6 |
| Non-nucleoside analogue reverse | 5 | 71.4 |
| Transcriptase inhibitor | ||
Note:
Not mutually exclusive categories
Characteristics related to the treatment of Kaposi's sarcoma of patients living with HIV AIDS, attended at an university hospital between the years 2004 and 2014
| Characteristics | Number | % |
|---|---|---|
| ART | 5 | 22.7 |
| Chemotherapy + ART | 17 | 77.3 |
| Liposomal doxorubicin | 7 | 31.8 |
| BV (bleomycin and vincristine) | 6 | 50.0 |
| ABV (adriamycin. bleomycin and vincristine) | 1 | 4.5 |
| Paclitaxel | 1 | 4.5 |
| Unknown[ | 2 | 9.1 |
Note:
Unknown information - not on medical chart.
Association of staging and outcome of Kaposi's sarcoma cases and ART use of patients living with HIV/AIDS, attended at an university hospital between the years 2004 and 2014
| Variables | All patients Patients using ART | p-value | |||||
|---|---|---|---|---|---|---|---|
| N | % | Yes | No | ||||
| N | % | N | % | ||||
| Low risk | 3 | 13.6 | 2 | 28.6 | 1 | 6.7 | 0.227 |
| High risk | 19 | 86.4 | 5 | 71.4 | 14 | 93.3 | |
| Complete remission | 9 | 40.9 | 2 | 28.6 | 7 | 46.7 | 0.346 |
| Partial remission | 1 | 4.5 | 0 | - | 1 | 6.7 | |
| Stable disease | 1 | 4.5 | 1 | 14.3 | 0 | - | |
| Disease progression | 2 | 9.1 | 0 | - | 2 | 13.3 | |
| Cure | 1 | 4.5 | 0 | - | 1 | 6.7 | |
| Death | 8 | 36.5 | 4 | 57.1 | 4 | 26.7 | |